RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
96 hedge funds and large institutions have $578M invested in RAPT Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 7 closing their positions.
4,631% more call options, than puts
Call options by funds: $9.89M | Put options by funds: $209K
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0.26% more ownership
Funds ownership: 12.39% → 12.65% (+0.26%)
2% less funds holding
Funds holding: 98 → 96 (-2)
9% less capital invested
Capital invested by funds: $637M → $578M (-$59M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$10.1M |
| 2 |
Millennium Management
New York
|
+$7.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.3M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$5.65M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.51M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.03M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.57M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$3.96M |
| 5 |
Morgan Stanley
New York
|
-$2.72M |
RAPT Hedge Fund Activity: Q3 2023 in Review
96 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2023, worth a combined $578M — down 9.3% from $637M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of RAPT and 5 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 37 added.
The largest buyer was Deep Track Capital, adding an estimated $10.1M. The largest seller was Perceptive Advisors, cutting an estimated $7.51M.
- 96 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2023, down from 98 in Q2 2023.
- Funds reported $578M of RAPT Therapeutics stock for Q3 2023, down 9.3% quarter-over-quarter.
- 5 funds opened new RAPT Therapeutics positions in Q3 2023 and 7 closed out, a net change of -2 holders.
- The largest RAPT Therapeutics buyer in Q3 2023 was Deep Track Capital, an estimated $10.1M added.
- The largest RAPT Therapeutics seller in Q3 2023 was Perceptive Advisors, an estimated $7.51M sold.
Based on aggregated 13F filings for Q3 2023.